Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect and safety of NN9535 (semaglutide) in weight management
jRCT2080224531Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of semaglutide in obesity (3 arms), sponsored by Novo Nordisk. Primary endpoints: Percent change in body weight from baseline, Proportion of weight loss responders (≥5%, ≥10%, ≥15%) and 1 more. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on jRCT2080224531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224531.